Why the study?
Does intensive glycemic control reduce the progression of renal disease compared with standard control in patients with type 2 diabetes?
Does intensive glycemic control reduce the progression of renal disease compared with standard control in patients with type 2 diabetes?
Intensive glycemic control does not significantly reduce overall renal disease progression in type 2 diabetes but may offer renoprotection in specific high-risk subgroups.
Intensive glycemic control should not target renal protection in T2D; confirms overall null effect while extending signals to microvascular subgroups.
OBJECTIVE: The Veterans Affairs Diabetes Trial (VADT) was a randomized, prospective, controlled trial of 1,791 patients with type 2 diabetes to determine whether intensive glycemic control would reduce cardiovascular events compared with standard control. The effect of intensive glycemic control and selected baseline variables on renal outcomes is reported. RESEARCH DESIGN AND METHODS: Baseline mean age was 60.4 years, mean duration of diabetes was 11.5 years, HbA(1c) was 9.4%, and blood pressure was 132/76 mmHg. The renal exclusion was serum creatinine >1.6 mg/dL. Renal outcomes were sustained worsening of the urine albumin-to-creatinine ratio (ACR) and sustained worsening by one or more stages in the estimated glomerular filtration rate (eGFR). RESULTS: Intensive glycemic control did not independently reduce ACR progression but was associated with a significant attenuation in the progression of ACR in those who had baseline photocoagulation, cataract surgery, or both. The beneficial effect of intensive glycemic control increased with increasing BMI and with decreasing diastolic blood pressure (DBP). Intensive glycemic control was associated with less worsening of eGFR with increasing baseline ACR and insulin use. Baseline systolic blood pressure, triglycerides, and photocoagulation were associated with worsening of eGFR. CONCLUSIONS: Intensive glycemic control had no significant effect on the progression of renal disease in the whole cohort but was associated with some protection against increasing ACR in those with more advanced microvascular disease, lower baseline DBP, or higher baseline BMI and on worsening of eGFR in those with high baseline ACR.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: